DBV Technologies | DBVT - Operating Expenses

Stock Price
22.39
Daily Change
0.80 3.71%
Monthly
31.78%
Yearly
394.26%
Q1 Forecast
21.05

DBV Technologies reported $37.05M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Amarin USD 51.37M 14.6M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
DBV Technologies USD 37.05M 4.06M Sep/2025
Halozyme Therapeutics USD 136.34M 13.06M Sep/2025
Incyte USD 4.65B 3.75B Sep/2025
Insmed USD 403.69M 42.4M Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
United Therapeutics USD 6.59B 6.07B Sep/2025